DOI: 10.1093/ced/llag272 ISSN: 0307-6938
A Multi-Centre Real-World Evaluation of Ritlecitinib in Severe Alopecia Areata: Early Real World Experience in a British Cohort
Danning Li, Radhika Bhanot, Sonika Sethi Nayyar, Vidette Wong, Kareem Hassanin, Graciaa Singhal, Sarah Elhabrouk, Donna Thompson, James Halpern, Simon Tso, Tang Ngee Shim, Kashini AndrewIn this UK multi-centre study of 54 patients with severe alopecia areata, oral ritlecitinib 50 mg daily achieved a 27.8% (15/54) success rate (SALT≤20) at six months, demonstrating real-world efficacy and safety profiles comparable to pivotal clinical trials. Notably, success was numerically lower in patients with skin of colour (13.3% vs. 33.3% in Caucasian patients), a subgroup that presented with significantly higher baseline disease severity and a higher likelihood of past DCP or systemic treatment.